MSD K.K.
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Banyu Pharmaceutical Co., Ltd. (to 2011)
31
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
- 5 terms have ended since Aug 23, 2026
- Nov 11 US 7,521,455 Fused ring 4-oxopyrimidine derivative · term ended
- Nov 8 US 7,491,720 Aminopyridine derivatives having Aurora A selective inhibitory action · term ended
- Sep 30 US 8,846,700 Heteroaryl Quinazoline Derivatives · lapsed on the fee record
- Sep 28 US 7,829,586 Aryl-substituted nitrogen-containing heterocyclic compounds · term ended
- Sep 26 US 7,700,611 Synthesis and Crystalline Forms of NPY5 Antagonist · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,030,327 | Fused imidazole derivative In force · USPTO record | In force | USPTO record | |
| US 7,799,820 | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions In force · USPTO record | In force | USPTO record | |
| US 8,268,842 | Fused ring 4-oxopyrimidine derivative In force · USPTO record | In force | USPTO record | |
| US 8,791,125 | Dihydropyrazolopyrimidinone derivatives In force · USPTO record | In force | USPTO record | |
| US 7,960,402 | Carbamoyl-substituted spiro derivative In force · USPTO record | In force | USPTO record | |
| US 7,994,331 | Heterocycle-substituted benzimidazole derivative In force · USPTO record | In force | USPTO record | |
| US 8,106,086 | Indoledione derivative In force · USPTO record | In force | USPTO record | |
| US 8,101,621 | Aminopyridine derivatives having aurora a selective inhibitory action In force · USPTO record | In force | USPTO record | |
| US 8,367,698 | 3-substituted sulfonyl piperidine derivative In force · USPTO record | In force | USPTO record | |
| US 7,834,019 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 31: 12 patents in force now held by others · 83 lapsed for an unpaid fee · 38 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 9 no status recorded
Rows 11 to 11 of 11 are for members. The first 10 are on the company page.
Pro members see all 11 published applications.